Nektar Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi. Good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce Nektar Therapeutics. We have Jonathan Zalevsky, Chief Research and Development Officer. Welcome. Thank you so much for joining us.
Thank you for having us.
To start, would you like to give a brief overview of Nektar and, I guess, the positive data that you had this year in two indications for those who may be newer to the story, and then we can move to some Q&A?
Great. Thanks. Thank you, Alice, and thank you to the conference organizers for the invitation. At Nektar, we really focus on our core strength of understanding immunology and immune regulation, coupling that with our other core competency in polymer chemistry to put those two things together in what we hope is the most disruptive way. We used that foundation to invent a molecule called rezpegaldesleukin, which is the native IL-2 sequence, using our polymer chemistry technology, which together make it a regulatory T-cell selective agonist. This has allowed us to advance REZPEG in a range of different indications that are all really aligned with regulatory T-cell intervention. Very topical, as the Nobel Prize last year was given to the three people really sort of that characteristically discovered immune tolerance and discovered regulatory T-cells.
REZPEG was one of the molecules that was actually named by the Nobel Committee as being the most advanced asset that uses that as a therapeutic hypothesis and strategy towards intervention. With REZPEG, we have seen data in multiple phase II studies. As you mentioned, most recently, we saw evidence of really disruptive effect in patients with moderate-to-severe atopic dermatitis, and we also followed that up with activity in patients with severe-to-very severe alopecia areata. Very true to the promise of a regulatory T-cell-focused treatment, what we saw across those indications was this very profound durability of the effect. I think characteristic with many drugs that we take day-to-day, they are drugs that usually work, hopefully for us, but then the effect sort of erodes over time.
What we see consistently across multiple studies with REZPEG is a durability and even a deepening of effect that as patients take the drug longer and longer, their symptoms and the underlying pathology of the disease really seems to improve. We can withdraw the drug and see durability of effect off treatment, which is sort of, we think, a new paradigm shift, which can either lead to very infrequent dosing or substantial drug holidays. We are excited that all of this has come together in multiple phase III programs that we have now initiated. Three registrational studies in atopic dermatitis that have all kicked off this summer. Actually, next month, in December, we will kick off a registrational program in alopecia areata. A very exciting time for Nektar with the potential of bringing the first regulatory T-cell targeting drug into the clinic and into registration.
Great. Thank you. Maybe we can start with REZPEG in atopic derm. We have some off-treatment data coming up soon, I think, from that one, which people are focusing on. What would be a positive outcome here? What should investors expect? Sure.
Well, maybe I will just take a moment to sort of set the table, right? Early on in REZPEG's development, we did a small phase I trial where we treated people for 12 weeks, and then we took people off drug for 36 additional weeks. We saw not only maintenance, but even deepening of effect over the first few months. All the way out to that nine-month endpoint, we saw a very high sustainment of both the 75% improvement in EASI score, EASI75, and also in the vIGA-AD 0/1 response as well. When we designed the phase II, which was a much larger 400-patient trial, we prospectively built in this kind of observational off-drug period to really sort of characterize this phenomenon that we observed in the phase I trial.
In this phase II study, and the data that you mentioned coming in the first quarter for us early in 2027, we've now seen people that have been treated for 52 weeks. These are patients that were treated in the induction, people that reached an EASI50 or better advanced into maintenance, where they stayed on the same dose, either monthly or quarterly, through week 52. From week 52 onwards, now we have an off-drug observation for a year off treatment. We will have There are 125 patients that completed that maintenance period that moved into the 52-week observation. 15 of them were on placebo, and 110 were on REZPEG. The placebo was there that maintained the blind. This study was unique because the patient had no intervention.
This is different than traditional placebo withdrawal trials, like you see in the phase III programs of approved agents like lebrikizumab or DUPIXENT or NEMLUVIO even, where they had a randomized withdrawal to placebo and sham injection. Whereas in our study, there was no treatment at all, so people were just observed off drug. For us, this is going to be a very exciting patient population because this is really going to start to prospectively really characterize this off-treatment effect. What's the definition of success, right? Getting back to your original question. All of the relevant benchmark data really does come from these placebo withdrawal trials. We tend to focus on DUPIXENT because it is the most successful and the most heavily represented, and the greatest-selling example in the atopic dermatitis class.
In a nine-month placebo withdrawal, they showed about a 50% durability of EASI75 across that nine-month interval. If we see that level of efficacy at 12 months, and again, that's not a placebo withdrawal, there was still a sham injection with DUPIXENT, whereas we have no treatment at all. If we see that level of activity at 12 months, we think that's a bar of success. Obviously, if it's north of that's truly inspirational. Our goal with sort of how that data fits into the paradigm of REZPEG is that it doesn't necessarily say you've cured the disease. I think it's a little early to have a discussion like that, but it does tell us that very low-frequency dose regimens, whether they're once a quarter, maybe even twice a year, those are definitely possible for a mechanism like REZPEG.
Okay, that's helpful. How important is the off-treatment data that you just described to maybe improving REZPEG's profile or filling out REZPEG's profile and its potential in atopic derm when you speak to KOLs?
Yeah, we think that it really speaks to this differentiation of the mechanism, right? Because traditionally, really, most drugs are very symptom-controlling. They are mostly antagonists and inhibitors. They block a pathway. This pathway is elevated in disease, say IL-13, for example. If you are on target, you can get disease control, but when the drug washes out, the effect of the disease comes back, right? So, it is like lower durability kind of approaches. Whereas if you are getting truly disease modification, you are fixing the underlying pathology, which a Treg could do, that starts to really sort of branch out the opportunity and the benefit for the patient.
Okay. Now, you have initiated your full phase III program, I think, now for atopic derm with REZPEG, ZENITH-AD, three trials. Can you remind us of the design for each of those trials and when they are expected to read out?
Yeah, sure. All three trials will enroll about 510 patients, and AD1 is a trial that focuses on adolescent and up, so ages 12 and up. All patients will have moderate to severe atopic dermatitis, and these are patients that we call biologic-naive, so they have been untreated with a systemic, no JAK inhibitor, no biologic. So, this is the truly first-line population for whom topical steroids or TCIs are no longer suitable to control their disease. AD2, the second study, is also in adolescents ages 12 and up, also with moderate to severe atopic dermatitis, same kind of disease features. But this is a trial where REZPEG is given in combination with topical corticosteroid. This patient population is a blend of both biologic-naive and biologic-experienced patients that have had prior DUPIXENT, lebri, NEMLUVIO, Adbry, and/or a JAK inhibitor.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
